International consensus diagnostic criteria for neuromyelitis optica spectrum disorders
Why is this work in the frame?
A frame that forgets how it found something cannot be audited. These are the routes that admitted this work.
No Canadian affiliation. An affiliation-only frame — the usual design — would never have seen this work. It is one of the works that make the case for inverting the frame.
Abstract
Neuromyelitis optica (NMO) is an inflammatory CNS syndrome distinct from multiple sclerosis (MS) that is associated with serum aquaporin-4 immunoglobulin G antibodies (AQP4-IgG). Prior NMO diagnostic criteria required optic nerve and spinal cord involvement but more restricted or more extensive CNS involvement may occur. The International Panel for NMO Diagnosis (IPND) was convened to develop revised diagnostic criteria using systematic literature reviews and electronic surveys to facilitate consensus. The new nomenclature defines the unifying term NMO spectrum disorders (NMOSD), which is stratified further by serologic testing (NMOSD with or without AQP4-IgG). The core clinical characteristics required for patients with NMOSD with AQP4-IgG include clinical syndromes or MRI findings related to optic nerve, spinal cord, area postrema, other brainstem, diencephalic, or cerebral presentations. More stringent clinical criteria, with additional neuroimaging findings, are required for diagnosis of NMOSD without AQP4-IgG or when serologic testing is unavailable. The IPND also proposed validation strategies and achieved consensus on pediatric NMOSD diagnosis and the concepts of monophasic NMOSD and opticospinal MS.
Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.
The record
- Venue
- Neurology
- Topic
- Multiple Sclerosis Research Studies
- Field
- Medicine
- Canadian institutions
- —
- Funders
- Chugai PharmaceuticalMitsubishi Tanabe Pharma CorporationNational Eye InstituteAstellas PharmaNovartis PharmaMinistry of Education, Science and TechnologyMultiple Sclerosis Society of CanadaEuropean Committee for Treatment and Research in Multiple SclerosisAlexion PharmaceuticalsNational Institute of Neurological Disorders and StrokeTeijin PharmaTeva Pharmaceutical IndustriesAcorda TherapeuticsViropharmaGlaxoSmithKlineBiogenOno PharmaceuticalEisaiNational Institutes of HealthGuthy-Jackson Charitable FoundationDaiichi Sankyo EuropeSanofi
- Keywords
- Neuromyelitis opticaMedicineMultiple sclerosisNeuroimagingConsensus conferenceSpinal cordSerologyPathologyOptic neuritisSpectrum disorderAquaporin 4AntibodyImmunologyInternal medicinePsychiatry
- Has abstract in OpenAlex
- yes